Real-world data shows one shot Sputnik Light vaccine (the first component of the Sputnik V vaccine) has high safety and 93.5% efficacy against COVID during vaccination in Paraguay

Moscow, August 18, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the data from Paraguay’s Ministry of Health on the one shot Russian Sputnik Light vaccine against coronavirus (the first component of the Sputnik V vaccine) demonstrating high safety profile and a 93.5% efficacy, as reported during the ongoing vaccination campaign in the country.

The one shot Sputnik Light vaccine has proven to be highly effective against COVID among more than 320,000 subjects who had received the vaccine based on the data collected by July 30, 2021. The data also indicates a high safety profile of Sputnik Light:

  • No serious adverse events associated with vaccination;

  • No deaths related to the vaccination;

  • No cerebral vein thrombosis (CVT) cases after vaccination;

  • No Guillain-Barre syndrome (GBS) cases after vaccination;

  • No capillary leak syndrome cases after vaccination;

  • No cases of myocarditis or pericarditis reported.

Thanks to its safety and efficacy, single-component Sputnik Light vaccine is now both used on standalone basis and also studied in combination with vaccines from other producers in a number of countries.

The heterogeneous boosting approach (“vaccine cocktail” using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world’s first registered vaccine against coronavirus. With this approach proving successful in creating a longer and more durable immunity against the coronavirus, RDIF took the lead in initiating partnerships with other vaccine producers to conduct joint studies of a combination of the first component of Sputnik V against COVID Russian Direct Investment Fund with foreign vaccines.

In particular, initial safety results of the world’s first study of a combination between Sputnik Light and the AstraZeneca vaccine in Azerbaijan demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination.

Also RDIF, Ministry of Health of Argentina, Ministry of Science of Argentina and CONICET are conducting a study for the evaluation of the immune response and safety of heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm and Moderna in the city and province of Buenos Aires, as well as San Luis, Cordoba and La Rioja provinces. The results of the study will be published in a peer-reviewed medical journal.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:

“The one shot Sputnik Light vaccine enables authorities of Paraguay to speed up the vaccination of the population and accelerate the creation of herd immunity. As demonstrated by data from the Ministry of Health of Paraguay, as well as and a number of other countries around the world, Sputnik Light has a high safety profile and one of the best efficacy numbers as compared to many two-shot vaccines.”

Key advantages of Sputnik Light:

  • Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

  • Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

  • Russian vaccine against coronavirus Gamaleya national center of epidemiology and microbiology Sputnik Light is compatible with standard vaccine storage and logistics requirements.

  • The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953).


Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 1 mn people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: [email protected]

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133

Message has been successfully sent!

Thank you!
You have been subscribed